Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim results and the acceptance of its NDA for PB-119 by the National Medical Products Administration of China [1] Financial Performance - The company reported other net income of RMB 178,000 and R&D expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] - The trading volume reached HKD 18.8928 million at the time of reporting [1] Product Development and Strategy - Peijia Medical anticipates commercializing PB-119 in China soon, following the acceptance of its NDA [1] - The company has successfully established a pipeline of six investigational drugs targeting chronic diseases [1] - The core strategy focuses on treating metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC) [1]